Giorgio Minotti

Jul 1, 2024 | jacc.org | Massimiliano Camilli |Carlo Maria Cipolla |Susan Dent |Giorgio Minotti

Introduction Since the 1980s, anthracyclines, including doxorubicin, daunorubicin, epirubicin, and idarubicin, have been central to treating various hematologic and solid malignancies, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (nHL), acute leukemias, breast cancer (BC), ovarian cancer, and sarcomas.1,2 In clinical practice, the application of anthracyclines is limited by a dose-dependent cardiotoxicity, leading to both systolic and diastolic cardiac dysfunction and, in less common...

Oct 9, 2023 | jpet.aspetjournals.org | Giorgio Minotti |Massimiliano Camilli

High plasma levels of low-density lipoprotein cholesterol (LDL-C) have long been known to associate with a measurable increase of cardiovascular (CV) events in the general population. LDL-C lowering drugs, from the venerable statins to ezetimibe and PCSK9 inhibitors, are therefore pillars of the clinical management of patients with high LDL-C, but the magnitude of reduction of CV events in the at-risk patients remains a matter of controversy.

Jul 18, 2023 | pubmed.ncbi.nlm.nih.gov | Giorgio Minotti

Skip to main page content Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day?

Jul 17, 2023 | jpet.aspetjournals.org | Giorgio Minotti

EditorialSpecial Section on Clinical Pharmacology—Editorial A Special Section on Clinical Pharmacology—Editorial Journal of Pharmacology and Experimental Therapeutics August 2023, 386 (2) 115-116; DOI: https://doi.org/10.1124/jpet.123.001743